scPharmaceuticals Inc. (SCPH)
NASDAQ: SCPH
· Real-Time Price · USD
5.67
0.01 (0.18%)
At close: Oct 03, 2025, 3:59 PM
5.65
-0.35%
After-hours: Oct 03, 2025, 04:11 PM EDT
0.18% (1D)
| Bid | 5.52 |
| Market Cap | 302.2M |
| Revenue (ttm) | 49.97M |
| Net Income (ttm) | -91.72M |
| EPS (ttm) | -1.81 |
| PE Ratio (ttm) | -3.13 |
| Forward PE | -35.38 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 5.94 |
| Volume | 3,750,613 |
| Avg. Volume (20D) | 1,656,803.5 |
| Open | 5.66 |
| Previous Close | 5.66 |
| Day's Range | 5.66 - 5.68 |
| 52-Week Range | 1.94 - 6.28 |
| Beta | 0.30 |
| Ex-Dividend Date | n/a |
About SCPH
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SCPH
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SCPH stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsscPharmaceuticals Inc. is scheduled to release its earnings on
Nov 12, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
+28.57%
scPharmaceuticals shares are trading higher after ...
Unlock content with
Pro Subscription
7 months ago
-1.89%
scPharmaceuticals shares are trading higher after the company announced FDA approval for a supplemental new drug application expanding the FUROSCIX indication to include the treatment of edema in patients with chronic kidney disease.
